MIR4755: A Potential Drug Target and Biomarker (G100616434)

MIR4755: A Potential Drug Target and Biomarker

MIR4755 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the mir family of genes, which encode for non-coding RNA molecules that have been implicated in various cellular processes. One of the functions of MIR4755 is to regulate the expression of genes that encode for proteins involved in the immune response and inflammation.

Recent studies have identified MIR4755 as a potential drug target in the context of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. MIR4755 has also been shown to be involved in the regulation of pancreatic cancer cell survival and the development of insulin resistance, which are important biomarkers for several types of cancer.

In addition to its potential clinical applications, MIR4755 has also generated significant interest among researchers due to its unique genetic and molecular properties. The MIR4755 gene is located on chromosome 19, which is known for its role in the development of genetic diseases. The gene is composed of 21 exons, and it encodes a protein that contains 543 amino acid residues.

The structure and function of MIR4755 have been studied using a variety of techniques, including biochemical, cellular, and genomic approaches. One of the most significant findings in these studies is that MIR4755 is involved in the regulation of gene expression and has a highly conserved architecture across different species. This conservation suggests that MIR4755 may be a good candidate for drug targeting in humans.

One of the key features of MIR4755 is its ability to interact with other proteins and molecules. This interaction has been observed in several studies, including cell-cell interactions and protein-protein interactions. For example, MIR4755 has been shown to interact with the protein known as NF-kappa-B, which is a transcription factor that plays a role in the regulation of gene expression and inflammation.

This interaction between MIR4755 and NF-kappa-B raises the possibility that MIR4755 may be a drug target that can be targeted by small molecules or other therapeutic agents. In fact, several studies have shown that MIR4755 is sensitive to such treatments and that inhibition of its interaction with NF-kappa-B can lead to the downregulation of gene expression and the inhibition of cellular processes.

Another potential mechanism by which MIR4755 may be targeted is its role in the regulation of cellular processes that are altered in many types of cancer. For example, MIR4755 has been shown to be involved in the regulation of cell cycle progression and the apoptosis, which are processes that are altered in many types of cancer.

In addition to its potential clinical applications, MIR4755 also has significant potential as a biomarker for several types of cancer. The expression of MIR4755 has been shown to be elevated in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, MIR4755 has been shown to be involved in the regulation of gene expression in cancer cells, which suggests that it may be a useful target for cancer therapies that target gene expression.

In conclusion, MIR4755 is a protein that has significant potential as a drug target and biomarker for several types of cancer. Its unique genetic and molecular properties, as well as its involvement in the regulation of cellular processes that are altered in many types of cancer, make it an attractive target for small molecules and other therapeutic agents. Further research is needed to fully understand the mechanisms of MIR4755's function in cancer and to develop effective therapies that can target it.

Protein Name: MicroRNA 4755

The "MIR4755 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4755 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4756 | MIR4757 | MIR4758 | MIR4759 | MIR4760 | MIR4761 | MIR4762 | MIR4763 | MIR4764 | MIR4765 | MIR4766 | MIR4767 | MIR4768 | MIR4769 | MIR4770 | MIR4771-1 | MIR4771-2 | MIR4772 | MIR4773-1 | MIR4773-2 | MIR4774 | MIR4775 | MIR4776-1 | MIR4776-2 | MIR4777 | MIR4778 | MIR4779 | MIR4780 | MIR4781 | MIR4782 | MIR4783 | MIR4784 | MIR4785 | MIR4786 | MIR4787 | MIR4789 | MIR4790 | MIR4791 | MIR4793 | MIR4794 | MIR4795 | MIR4796 | MIR4797 | MIR4798 | MIR4799 | MIR4800 | MIR4802 | MIR4803 | MIR4804 | MIR483 | MIR484 | MIR485 | MIR486-1 | MIR486-2 | MIR487A | MIR487B | MIR488 | MIR489 | MIR490 | MIR491 | MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B | MIR5000 | MIR5001 | MIR5002 | MIR5003 | MIR5004 | MIR5006 | MIR5007 | MIR5008 | MIR5009 | MIR500A | MIR500B | MIR501 | MIR5010 | MIR5011 | MIR502 | MIR503 | MIR503HG | MIR504 | MIR5047 | MIR505 | MIR506 | MIR507 | MIR508 | MIR5088 | MIR5089 | MIR509-1 | MIR509-2 | MIR509-3 | MIR5090